PEANUT ALLERGY VACCINE MARKET ANALYSIS

Market News

Key Developments

1. Major market players are involved in different business strategies such as research and development, in order to develop effective vaccine for peanut allergy. For instance, in February 2019, Aravax, an Australia-based biotechnology company, presented positive Phase I data for clinical trial, evaluating safety and tolerability of a novel vaccine ‘PVX108’ at 2019 American Academy of Allergy, Asthma & Immunology (AAAAI). This is an intradermal peanut allergy immunotherapy vaccine.
2. Major market players are involved in different business strategies such as gaining approval from regulatory authorities, in order to develop effective vaccine for peanut allergy. For instance, in March 2019, Aimmue Therapeutics, Inc., a biopharmaceutical company, received Biologics License Application (BLA) for AR101 from the U.S. Food and Drug Administration (FDA) for review. AR101 is indicated for peanut allergy.
3. Major market players are involved in different business strategies such as partnership and collaboration, in order to develop effective vaccine for peanut allergy. For instance, Sementis, an Australia-based biotechnology company, collaborated with Ensi Pharama, a U.K.-based company, development and evaluation of peanut allergy vaccine.